Table 2.

Phenotypic Profile of 197 Isolates Studied

	Susceptibility Status by Drug
No. of Isolates	Ceftolozane/Tazobactam	Ceftazidime/Avibactam
138	S	S
6	S	R
14	R	S
39	R	R
Total	144 S, 53 R	152 S, 45 R

US Food and Drug Administration breakpoints were used for determining ceftolozane/tazobactam (S ≤ 4, I = 8, R > 8) and ceftazidime/avibactam (S ≤ 8, R > 8) susceptibility status. For the purposes of this study, an intermediate phenotype was also considered as R.

Abbreviations: R, resistant; S, susceptible.